Effect of DPP-IV Inhibitor on Glycemic Control and Autonomic Neuropathy in Adult Patients With Diabetes Mellitus
Status:
Unknown status
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
Rocca et al. reported first that the secretion of incretins, particular GLP-1 in rat is
regulated by the enteric nervous system, the afferent and efferent vagus nerves [1]. Further,
Kazakos et al. [2] reported that autonomic nerve disturbance (AND) in patients with T2DM
impaired the incretin effect owing to decreased GLP-1 secretion. However, Toft-Nielsen et al.
[3] reported that the decreased GLP-1 responses in the patients with type 2 diabetes mellitus
(T2DM) are unlikely to be related to the AND and, thus, did not support the results of Rocca
et al. and Kazakos et al. Recently, Yabe at al. [4] also observed the same observations in
Japanese patients with T2DM. Meanwhile, Jin et al. reported that administration of DPP-IV
inhibitor recovered the disturbance of diabetic nerve dysfunction in rat [5]. However, it is
unknown whether the administration of DPP-IV inhibitor effects on the AND in human, although
many studies are performed to investigate the effect of the DPP-IV inhibitors on glycemic
control.
Accordingly, it is significant to reinvestigate an effect of DPP-IV inhibitor on glycemic
control and autonomic neuropathy in diabetic patients.